Moderna (MRNA.US) saw its pre-market shares surge over 5% after its world's first mRNA flu vaccine, mRNA-1010, received approval from the U.S. FDA for market launch, becoming the company's fifth approved product. This marks the expansion of mRNA technology from emergency use in COVID-19 vaccines to the conventional vaccine market. Additionally, the company reported revenues of $145 million in the second quarter of 2026, surpassing market expectations.